European Society of Gynaecological Oncology (ESGO) — ESGO Congress 2027

Event overview (official details)

• Event name: ESGO 2027 Congress
• Dates: February 25 – 27, 2027
• City & country: London, United Kingdom
• Event type / format: International scientific congress focused on gynaecological cancers, featuring education, networking, guidelines, practical demonstrations, and live surgery transmissions.
• Positioning: ESGO describes the Congress as the largest European gathering in gynaecological cancers and Europe’s landmark meeting in gynaecological oncology.

1️⃣ Who attends (BUYERS / ATTENDEES)

ESGO 2027 is a clinical and scientific congress, so the strongest “buyers” we typically target are the decision-makers and influencers who care about clinical adoption, evidence generation, guideline-aligned care, and procurement of medical solutions. The audience includes a mix of clinicians, academic leaders, research communities, and industry stakeholders.

Buyer/decision-maker attendee groups most likely represented:

• Medical and clinical leadership in gynaecologic oncology: surgeons, medical oncologists, radiation oncology stakeholders (where relevant), and multidisciplinary care leaders.
• Academic & research leadership: university hospital leaders, clinical researchers, translational medicine teams.
• Guideline and education influencers: members of scientific committees, guideline authors, and senior clinical educators shaping practice pathways.
• Industry medical affairs & evidence teams: roles responsible for clinical evidence, peer education, scientific communications, and clinical program strategy.
• Clinical operations & trial leadership: teams involved in study planning, investigator engagement, and site coordination (often aligned to industry sponsors and CROs).
• Market access / health economics stakeholders: professionals focused on reimbursement rationale, value dossiers, and outcomes evidence.
• Procurement-adjacent participants: depending on organiser ecosystem and partner participation, hospital procurement and service evaluation teams may attend, especially for devices and diagnostics.

A key note for buyer fit: because the Congress emphasises research, guidelines, practical demonstrations, and live surgery transmissions, the “best buyer” profiles typically skew toward teams that can act on clinical credibility (medical affairs, clinical evidence, clinical operations, market access) rather than purely general marketing roles.

2️⃣ Where the show is happening + attendee geographic origin

• Venue city/country (official): London, United Kingdom

ESGO 2027’s audience is described as coming from around the world. The official page also highlights strong international reach metrics: 100+ international speakers, 100+ countries represented, and 4,000+ attendees. That strongly indicates a global attendee origin mix with a European base.

Practical geographic targeting guidance (based on official “countries/speakers” claims):

• Primary: Europe (multi-country, multi-language scientific community)
• Secondary: UK-wide and pan-European research hospitals and society-aligned stakeholders
• Global participation: North America, Middle East, and Asia-Pacific research and industry stakeholders who track late-breaking research and guidelines

3️⃣ Audience reach (Local / National / Global)

This is a global congress with Europe at its core. ESGO specifically positions the Congress as Europe’s landmark meeting, while the official page also states:

• 4,000+ attendees from around the world
• 100+ countries
• 100+ international speakers

Therefore, the audience reach is best characterised as Global (Europe-led).

4️⃣ Sample buyer company names (BUYERS ONLY) + websites

Below is a buyer-style sample set (industry stakeholders who commonly engage with clinical oncology congress ecosystems). These are suggested targets for outreach and research, not a guarantee of exhibitor status.

Buyer targeting table (15–20 sample buyers)

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Roche	https://www.roche.com	Global Medical Affairs Director / Oncology Medical Director	Strong oncology portfolio and evidence-generation footprint; medical affairs leaders align to late-breaking research, peer education, and guideline-adjacent education.
2	Pfizer	https://www.pfizer.com	VP, Medical Affairs (Oncology) / Clinical Evidence Lead	Oncology development and medical education needs; congress attendance is highly relevant for clinical updates and investigator engagement.
3	Merck & Co. (MSD)	https://www.merck.com	Director, Clinical Operations / Oncology Clinical Program Lead	Clinical operations and oncology programs benefit from congress visibility with specialist communities and research networks.
4	Bristol Myers Squibb (BMS)	https://www.bms.com	Head of Medical Affairs / Evidence Strategy Lead	Oncology evidence and education strategy aligns well with guideline discussions and scientific programme highlights.
5	AstraZeneca	https://www.astrazeneca.com	Medical Director, Oncology / Real-World Evidence (RWE) Lead	Oncology medical strategy and evidence creation map to peer-to-peer interactions, late-breaking research, and care pathway discussions.
6	Johnson & Johnson (Janssen)	https://www.jnj.com	Global Medical Affairs Director, Oncology / Clinical Trial Governance Lead	Janssen’s oncology activity typically requires specialist conferences for scientific credibility and research engagement.
7	GSK	https://www.gsk.com	Director, Medical Affairs / Clinical Development Lead (Oncology)	Medical affairs leadership fits the congress’s emphasis on discoveries, guidelines, and clinical education.
8	Novartis	https://www.novartis.com	Head of Medical Affairs (Oncology) / Clinical Evidence Manager	Oncology-focused evidence and patient-centred care narratives align with ESGO’s stated goals and scientific programme.
9	Sanofi	https://www.sanofi.com	Therapeutic Area Medical Director / Oncology Clinical Operations Manager	Medical and clinical operations teams commonly seek specialist conference access for research alignment and KOL engagement.
10	Thermo Fisher Scientific	https://www.thermofisher.com	Director, Clinical Trials Solutions / Oncology Research Solutions Lead	Supports diagnostics, lab services, and trial enablement—high relevance to research-heavy oncology congress formats.
11	Siemens Healthineers	https://www.siemens-healthineers.com	Oncology Clinical Specialist / Head of Clinical Evidence (Imaging)	Imaging and diagnostic technology adoption often hinges on clinical evidence; congress settings support alignment with specialist pathways.
12	Agilent Technologies	https://www.agilent.com	Director, Clinical Research Solutions / Life Sciences Market Development Lead	Life sciences and clinical research enablement aligns with oncology trial workflows and abstract-heavy scientific programmes.
13	Medtronic	https://www.medtronic.com	Clinical Marketing Manager / Global Product Specialist, Oncology Systems	Surgical and technology workflows benefit from congress visibility, especially where live surgical transmissions and practical demonstrations matter.
14	Varian (a Siemens Healthineers company)	https://www.varian.com	Clinical Affairs Director / Radiation Oncology Solutions Leader	Radiation oncology and integrated cancer care discussions connect strongly to multidisciplinary treatment updates.
15	IQVIA	https://www.iqvia.com	VP, Oncology Real-World Evidence / Clinical Solutions Director	RWE and evidence strategy often ties to guidelines, outcomes research, and late-breaking scientific communities.
16	Syneos Health	https://www.syneoshealth.com	Executive Director, Clinical Development / Oncology Strategy Lead	Clinical development and trial enablement partners frequently seek congress access to connect with research leadership.
17	PAREXEL	https://www.parexel.com	Oncology Clinical Trial Lead / Director, Site & Investigator Engagement	Trial operations and site engagement strongly benefit from specialized oncology congress ecosystems.
18	CROMSOURCE	https://www.crmscource.com	Director, Clinical Operations / Oncology Clinical Research Lead	CROs that focus on oncology research workflows have a natural reason to engage in abstract-heavy, evidence-focused events.
19	Merck KGaA (Germany)	https://www.merckgroup.com	Medical Affairs Director / Clinical Program Manager	Oncology science and clinical evidence activities align with Europe-led global congress participation.
20	BD (Becton, Dickinson and Company)	https://www.bd.com	Clinical Solutions Manager / Oncology Procedure Solutions Lead	Procedure and clinical workflow solutions can align with practical demonstrations and surgical-adjacent engagement themes.

“Top first outreach” shortlist (best immediate buyer density)

If we need to send the most relevant list first, we recommend prioritising buyer teams that most directly map to ESGO’s scientific and clinical evidence emphasis:

1. Roche
2. Merck & Co. (MSD)
3. AstraZeneca
4. Thermo Fisher Scientific
5. IQVIA
6. Syneos Health

5️⃣ Job profiles, industries & event type

Best job profiles to target

• Oncology Medical Director / Medical Affairs Director
• Clinical Evidence / Evidence Strategy Lead
• Clinical Trials / Clinical Operations Director
• Clinical Development Program Lead (Oncology)
• Real-World Evidence (RWE) Manager
• Market Access / Health Economics & Outcomes Research (HEOR) Lead
• Oncology Product Manager / Clinical Specialist
• Global / Regional Scientific Communications Lead
• Oncology KOL Engagement / Investigator Relations Director
• Innovation / Translational Research Partnerships Lead

Industries & event type (aligned to the congress’s purpose)

Event type: Medical & clinical oncology congress, education and research dissemination, guideline-aligned discussion, and specialist networking.

Best-fit industry categories from our standard industry mapping (based on the ESGO Congress theme):

• Hospital & Health Care
• Pharmaceuticals
• Medical Devices
• Biotechnology
• Research
• Information Technology & Services (only when tied to clinical data platforms / oncology informatics)
• Outsourcing/Offshoring (for CRO/clinical operations services)
• Management Consulting (only for HEOR/value strategy teams)

6️⃣ Estimated attendance (expected total footfall)

ESGO’s official page states: “over 4,000 attendees”. It also provides additional scale indicators: 3800+ Attendees, 100+ international speakers, 1500+ abstracts, and 200+ lectures.

Estimated attendance (footfall): ~4,000+ total delegates attending across Feb 25–27, 2027.

Buyer density will be shaped by the mix of: (1) clinical researchers and senior clinicians, and (2) industry medical affairs, clinical operations, and evidence teams who align to congress learning and networked discussions.

7️⃣ Key focus areas & buyer engagement

Core programme themes (from official description):

• Discovery and late-breaking research
• New guidelines
• Practical demonstrations
• Exclusive live surgery transmissions
• Peer-to-peer interactions
• Scientific excellence and patient-centred care
• Education and skills advancement

Buyer engagement angles that typically convert in this environment:

• Evidence-led messaging: position offerings around outcomes, guideline relevance, and clinical data.
• Clinical workflow fit: connect solutions to what clinicians will demonstrate and apply (especially where practical demos and surgical transmissions are highlighted).
• Late-breaking and abstract visibility: target medical affairs and clinical evidence leaders who actively monitor abstract submissions and lecture themes.
• Multidisciplinary oncology approach: align to patient-centred care narratives and multidisciplinary tumour care improvements.

8️⃣ Client-product fit note + request for client website (to refine “best buyers”)

We can refine the “best buyer” shortlist (and the job-title targeting) based on our client’s exact product category and positioning on their website. Because buyer relevance changes dramatically depending on whether the product is:

• a pharmaceutical/biologic therapy,
• a diagnostic or companion testing solution,
• a medical device / surgical technology,
• a CRO / clinical operations service, or
• an oncology informatics / data platform.

Please share the client website URL (and if available, product category + target customer type). We will then:

• re-rank the buyer table above to the highest fit companies,
• adjust the “Best Title to Target” to match the client’s buying roles, and
• map the best-fit industry filters for lead sourcing using our standard industry list.

What we need from you (quick checklist):

• Client website (required)
• Product/service type (pharma / device / diagnostics / CRO / informatics / other)
• Primary buyer type (medical affairs, clinical operations, procurement, R&D, market access, etc.)
• Regions served (EU only vs global)

9️⃣ Final buyer recommendation (industry-suggested targeting)

Based on ESGO 2027’s evidence-led, oncology-focused congress format and the official signals of international reach (100+ countries; 4,000+ attendees), the most effective buyer list typically comes from the following industries:

• Pharmaceuticals
• Biotechnology
• Medical Devices
• Hospital & Health Care (when targeting research hospitals, academic medical centres, oncology program leadership)
• Research (trial networks, translational research groups, evidence teams)
• Outsourcing/Offshoring (CROs / clinical services)
• Information Technology & Services (only where the solution is tied to oncology data, trial systems, or clinical decision support)

Suggested top outreach bundle: Medical Affairs leadership (oncology), Clinical Evidence/RWE, Clinical Operations (oncology trials), and Oncology Product/Clinical Specialists for device/diagnostics—because ESGO’s content emphasis (guidelines, demonstrations, and live surgical transmissions) usually drives high-value conversations for these roles.

---

Data we reliably have from the official ESGO Congress page

• Event: ESGO 2027 Congress
• Date: February 25 – 27, 2027
• Location: London, United Kingdom
• Audience scale: 4,000+ attendees (also shown as 3800+), 100+ international speakers, 100+ countries
• Programme scale: 1500+ abstracts, 200+ lectures
• Congress positioning: largest European gathering in gynaecological cancers; Europe’s landmark meeting in gynaecological oncology

Note: To finalize the best buyer set for our client’s requirements, we still need the client website URL so we can accurately match product-to-buyer roles.